Last reviewed · How we verify
Palbociclib 125mg (palbociclib-125mg)
At a glance
| Generic name | palbociclib-125mg |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Dyspnea
- Skin and subcutaneous tissue disorders - Other
- Neutrophil count decreased
- White blood cell decreased
- Anemia
- General disorders and administration site conditions
- Hyponatremia
- Lymphocyte count decreased
- Pain
- Blood and lymphatic system disorders - Other
- Renal and urinary disorders - Other
- Ankle fracture
Key clinical trials
- Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palbociclib 125mg CI brief — competitive landscape report
- Palbociclib 125mg updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI